Long-term Outcomes and Biomarker Correlates of a Multi-institutional Phase II Study of Hypofractionated Proton Beam Therapy for Unresectable Primary Liver Tumors

PURPOSE: To evaluate long-term outcomes and determine whether longitudinal plasma profiling provides biological insight into disease progression after proton hypofractionated ablative radiation therapy (HART) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). PATIENTS AND METHODS: In this single-arm, multi-institutional phase II trial, 92 patients with localized unresectable HCC or ICC with Child-Pugh class A/B liver function received HART (up to 67.5 GyE in 15 fractions). Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Plasma samples were collected at baseline, days 1, 8, 15, and 1-month after treatment for exploratory correlative analyses. RESULTS: Among evaluable patients (44 HCC, 39 ICC), median OS was 29.2 months (HCC) and 20.8 months (ICC), with 5-year OS rates of 25.9% and 12.3%, respectively. Median PFS was 13.8 months (HCC) and 8.4 months (ICC). In-field local failure occurred in 2 HCC (4.5%) and 7 ICC (17.9%) patients, whereas out-of-field intrahepatic/distant progression remained the predominant pattern of failure. No grade >3 treatment-related toxicities were observed. Exploratory plasma profiling identified distinct biological signatures associated with progression: HCC was characterized by markers of hypoxia, inflammation, vascular remodeling, stromal activation, and hepatic regeneration, whereas associations in ICC predominantly involved signatures of hypoxia and vascular remodeling. CONCLUSIONS: HART provides durable long-term in-field local control with minimal toxicity, but disease progression remains predominantly out-of-field intrahepatic/distant. Exploratory correlative analyses suggest that biological signatures reflecting vascular remodeling, hypoxia, inflammation, stromal activation, and hepatic reserve are associated with progression despite successful local therapy, informing future translational studies and combination strategies.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-18
DOI
https://doi.org/10.1158/1078-0432.ccr-26-1848
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-term Outcomes and Biomarker Correlates of a Multi-institutional Phase II Study of Hypofractionated Proton Beam Therapy for Unresectable Primary Liver Tumors

Zoe Guan, Christopher H. Crane, Joseph Wang Franses, Leilana Ly et al.
1 links
Clinical Cancer Research
Hepatocellular Carcinoma Treatment and Prognosis
article

Long-term Outcomes and Biomarker Correlates of a Multi-institutional Phase II Study of Hypofractionated Proton Beam Therapy for Unresectable Primary Liver Tumors

Zoe Guan, Christopher H. Crane, Joseph Wang Franses, Leilana Ly, Thomas F. DeLaney, Dan Gabriel Duda, Eugene Jon Koay, Kenneth K. Tanabe, Theodore Sunki Hong, Lipika Goyal, Edgar Ben‐Josef, Cristina Rosa Ferrone, David P. Ryan, Jennifer Yon-Li Wo, Hannah Johnson Roberts, Jeffrey William Clark, Andrew Xiuxuan Zhu, Jill N. Allen, Lorraine C. Drapek, Beow Yong Yeap
article en

Abstract

PURPOSE: To evaluate long-term outcomes and determine whether longitudinal plasma profiling provides biological insight into disease progression after proton hypofractionated ablative radiation therapy (HART) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). PATIENTS AND METHODS: In this single-arm, multi-institutional phase II trial, 92 patients with localized unresectable HCC or ICC with Child-Pugh class A/B liver function received HART (up to 67.5 GyE in 15 fractions). Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Plasma samples were collected at baseline, days 1, 8, 15, and 1-month after treatment for exploratory correlative analyses. RESULTS: Among evaluable patients (44 HCC, 39 ICC), median OS was 29.2 months (HCC) and 20.8 months (ICC), with 5-year OS rates of 25.9% and 12.3%, respectively. Median PFS was 13.8 months (HCC) and 8.4 months (ICC). In-field local failure occurred in 2 HCC (4.5%) and 7 ICC (17.9%) patients, whereas out-of-field intrahepatic/distant progression remained the predominant pattern of failure. No grade >3 treatment-related toxicities were observed. Exploratory plasma profiling identified distinct biological signatures associated with progression: HCC was characterized by markers of hypoxia, inflammation, vascular remodeling, stromal activation, and hepatic regeneration, whereas associations in ICC predominantly involved signatures of hypoxia and vascular remodeling. CONCLUSIONS: HART provides durable long-term in-field local control with minimal toxicity, but disease progression remains predominantly out-of-field intrahepatic/distant. Exploratory correlative analyses suggest that biological signatures reflecting vascular remodeling, hypoxia, inflammation, stromal activation, and hepatic reserve are associated with progression despite successful local therapy, informing future translational studies and combination strategies.

Clinical Cancer Research
Cedars-Sinai Medical Center (US), Dartmouth–Hitchcock Medical Center (US), Houston Methodist (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Palo Alto University (US), Somerville Hospital (US), University of Chicago (US), University of Chicago Medical Center (US), Massachusetts General Hospital (US), Methodist Hospital (US), Dana-Farber Cancer Institute (US), Stanford Medicine (US), University of Pennsylvania (US), Philadelphia University (US), Stanford University (US)
National Cancer Institute, Department of Defense Education Activity
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon